Compare Gilead Sciences, Inc. (GILD) vs iShares Core MSCI Emerging Markets ETF (IEMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares Core MSCI Emerging Markets ETF — how do they compare? Gilead Sciences, Inc. trades at $135.36 (market cap $163.51B), while iShares Core MSCI Emerging Markets ETF trades at $78.11. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while iShares Core MSCI Emerging Markets ETF pays none, and iShares Core MSCI Emerging Markets ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| GILD | IEMG | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $155.80 | $86.00 |
52-Week Low | $108.22 | $59.90 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
The iShares Core MSCI Emerging Markets ETF (IEMG) trades at $78.08, down 2.06% on the day, with technical indicators showing a bearish bias. The fund has delivered strong recent performance, surging approximately 35% over the past year according to The Motley Fool (2026-06-24), driven by significant exposure to South Korean and Taiwanese technology stocks. Recent news highlights record inflows into emerging markets and IEMG's competitive 0.09% expense ratio compared to peers.
Outlook: IEMG offers concentrated, cost-effective exposure to high-growth emerging markets at a valuation discount to U.S. equities, but carries elevated volatility and geopolitical risks. Key opportunities include AI-driven tech exposure and strong dividend growth, while risks involve concentration in specific regions and sensitivity to U.S.-China tensions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →
